QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Franklin Gaylis, MD, is a urologist, Executive Medical Director of Unio Health Partners, Chief Scientific Officer of Genesis PC,and Professor of Urology at UC San Diego. He lectures nationally and internationally on healthcare quality and cost. In the early 1990s,…
The American Cancer Society projects that in 2026, there will be about 2.1 million new cancer cases and 626,140 cancer deaths in the United States. Although cancer remains a major cause of death, the mortality rate has continued to decline…
The IMPACT study evaluated whether annual prostate-specific antigen (PSA) screening is effective for early detection of prostate cancer in men with inherited BRCA1 or BRCA2 mutations, which are known to increase cancer risk. The study followed over 3,000 men…
Treatment approaches for patients with localized low-risk prostate cancer who have a life expectancy greater than 10 years include radical prostatectomy, radiotherapy , active surveillance (AS), and focal ablative therapy . Since only about 3% of such patients experience disease…
This population-based study from Norway evaluated adherence to national guidelines when enrolling men with newly diagnosed prostate cancer into active surveillance (AS) between 2009 and 2022. Among nearly 70,000 patients, about 16% were managed with AS. Overall, 64% of these…
This prospective study assessed whether adding polygenic risk scores (PRS) to standard clinical markers can more efficiently guide MRI usage in men with suspected prostate cancer. The results showed that PRS was a strong, statistically significant predictor of MRI positivity…
A recent retrospective study evaluated high-resolution micro-ultrasound (MUS) as an imaging-based screening and risk-stratification tool for prostate cancer in 682 men undergoing routine examination with PSA testing. Micro-ultrasound findings were scored and further refined by PSA density (PSAD) to define…
Several recent articles have focused on celebrities who have battled prostate cancer. For example, “Dilbert” cartoonist Scott Adams died on January 13, 2026, after confronting an aggressive form of the disease. While every cancer death is a tragedy ,…
This long-term analysis of over 160,000 European men examined whether PSA-based screening for prostate cancer effectively reduces mortality over 23 years. After a median follow-up of 23 years, PSA screening reduced prostate cancer mortality by 13% compared to no screening,…
This narrative review analyzed 85 studies (2009–2025) to assess the safety and outcomes of active surveillance (AS) in intermediate-risk prostate cancer, with AS eligibility typically including patients with favorable intermediate-risk features such as low-volume Gleason 3+4 disease, low PSA density…
"*" indicates required fields
